Pharmaceuticals
99 companies · ₹23.8 L cr · 14 with AI deep dives
5y revenue CAGR
median 8.89%(p25 5.79% · p75 12.46%)
5y avg ROCE
median 14.14%(p25 9.72% · p75 20.34%)
Debt / equity
median 0.26x(p25 0.07x · p75 0.44x)
AI sector brief
from the bucket's latest earnings calls · as of 2026-03-31headwindGeopolitical disruption driving broad-based freight, solvent and raw-material cost inflation9 managements
Nine of fourteen covered managements flagged elevated input costs directly tied to Middle East geopolitical disruptions: ocean and air freight rates, solvent prices, crude-linked…
- LUPIN (Q4 FY26): “When it comes to freight for example, ocean freight is about 15% higher, air freight is…”
tailwind7 managements🔒tailwind5 managements🔒headwind4 managements🔒tailwind4 managements🔒headwind3 managements🔒
5 more themes from this quarter's earnings calls are locked. A free account opens the full brief: every theme with verbatim management quotes, the demand picture, companies running against the tide, and the regulatory & disruption watch. Sign up free →
| Company | Mcap | AI verdict | Signals | Stated KPIs (latest call) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4.3 L cr | 🔒 unlock to view | earnings quality strongnet cash | |
| Divis Laboratories Ltd | ₹1.8 L cr | - | capex coming onlinepharma capex digesting | |
| Torrent Pharmaceuticals Ltd | ₹1.5 L cr | - | latent operating leverageearnings quality stronglevering upstory tension | |
| Cipla Ltd | ₹1.1 L cr | - | earnings quality strongnet cash | |
| Zydus Lifesciences Ltd | ₹1.1 L cr | - | ||
| Dr Reddys Laboratories Ltd | ₹1.1 L cr | - | latent operating leverageearnings quality strong | |
| Lupin Ltd | ₹1.0 L cr | 🔒 unlock to view | earnings quality strongstory tension | |
| Mankind Pharma Ltd | ₹98,228 cr | - | latent operating leverageearnings quality strong | |
| Aurobindo Pharma Ltd | ₹85,262 cr | - | capex coming onlineearnings quality strongpharma capex digesting | |
| Laurus Labs Ltd | ₹75,137 cr | 🔒 unlock to view | earnings quality strong | |
| Biocon Ltd | ₹67,632 cr | 🔒 unlock to view | earnings quality strongdeleveraging | |
| Alkem Laboratories Ltd | ₹63,352 cr | - | story tension | |
| Glenmark Pharmaceuticals Ltd | ₹61,116 cr | - | earnings quality strongstory tension | |
| Ipca Laboratories Ltd | ₹40,314 cr | - | earnings quality strongnet cash | |
| Ajanta Pharma Ltd | ₹39,355 cr | - | roce compoundernet cash | |
| Gland Pharma Ltd | ₹37,202 cr | 🔒 unlock to view | latent operating leveragenet cash | |
| J B Chemicals & Pharmaceuticals Ltd | ₹36,254 cr | - | roce compounderearnings quality strong | |
| Glaxosmithkline Pharmaceuticals Ltd | ₹35,914 cr | - | roce compounderearnings quality strong | |
| Emcure Pharmaceuticals Ltd | ₹33,083 cr | 🔒 unlock to view | roce compounderearnings quality strong | |
| Wockhardt Ltd | ₹31,442 cr | - | capex coming onlinedeleveragingstory tensionpharma capex digesting | |
| Sai Life Sciences Ltd | ₹25,710 cr | 🔒 unlock to view | earnings quality strongnet cash | |
| Neuland Laboratories Ltd | ₹22,067 cr | 🔒 unlock to view | earnings quality strongstory tension | |
| Piramal Pharma Ltd | ₹21,735 cr | - | deleveraging | |
| Pfizer Ltd | ₹20,641 cr | - | roce compoundernet cashstory tension | |
| Astrazeneca Pharma India Ltd | ₹20,581 cr | - | earnings quality weak | |
| ERIS Lifesciences Ltd | ₹19,410 cr | - | earnings quality strong | |
| Granules India Ltd | ₹18,969 cr | 🔒 unlock to view | earnings quality strongstory tension | |
| OneSource Specialty Pharma Ltd | ₹18,398 cr | - | ||
| Caplin Point Laboratories Ltd | ₹18,357 cr | - | capex coming onlineroce compoundernet cashstory tension | |
| Cohance Lifesciences Ltd | ₹16,328 cr | - | latent operating leveragemargin under pressureearnings quality strongnet cash | |
| Jubilant Pharmova Ltd | ₹15,530 cr | 🔒 unlock to view | capex coming onlinemargin under pressureearnings quality strongdeleveraging | |
| Natco Pharma Ltd | ₹15,475 cr | - | net cash | |
| Alembic Pharmaceuticals Ltd | ₹14,646 cr | - | earnings quality strongpharma capex digesting | |
| Concord Biotech Ltd | ₹14,196 cr | - | ||
| Alivus Life Sciences Ltd | ₹12,826 cr | - | capex coming onlineroce compoundercapex ahead of revenuepharma capex digesting | |
| Marksans Pharma Ltd | ₹11,406 cr | - | net cash | |
| Viyash Scientific Ltd | ₹10,917 cr | 🔒 unlock to view | latent operating leverageearnings quality strongstory tension | |
| Shilpa Medicare Ltd | ₹10,698 cr | - | capex coming onlineearnings quality strongstory tensionpharma capex digesting | |
| Sanofi Consumer Healthcare India Ltd | ₹10,698 cr | 🔒 unlock to view | roce compounderearnings quality strong | |
| Procter & Gamble Health Ltd | ₹10,345 cr | - | roce compounderstory tension | |
| Akums Drugs & Pharmaceuticals Ltd | ₹9,806 cr | - | earnings quality strongnet cash | |
| Strides Pharma Science Ltd | ₹9,770 cr | - | deleveragingpharma capex digesting | |
| Blue Jet Healthcare Ltd | ₹8,881 cr | - | capex coming onlineroce compounderpharma capex digesting | |
| Supriya Lifescience Ltd | ₹7,839 cr | - | latent operating leveragestory tension | |
| Sun Pharma Advanced Research Company Ltd | ₹7,286 cr | - | capex coming online | |
| Sanofi India Ltd | ₹7,179 cr | - | roce compounder | |
| FDC Ltd | ₹6,312 cr | - | ||
| Senores Pharmaceuticals Ltd | ₹5,946 cr | 🔒 unlock to view | capex coming onlineearnings quality weak | |
| Aarti Pharmalabs Ltd | ₹5,832 cr | - | latent operating leveragecapex coming onlineearnings quality strongcapex ahead of revenue | |
| Innova Captab Ltd | ₹5,408 cr | 🔒 unlock to view | ||
| Orchid Pharma Ltd | ₹4,671 cr | - | capex coming onlineearnings quality strongcapex ahead of revenue | |
| Bliss GVS Pharma Ltd | ₹4,623 cr | - | earnings quality strongnet cash | |
| IOL Chemicals & Pharmaceuticals Ltd | ₹3,946 cr | - | margin under pressureearnings quality strongnet cash | |
| Gufic BioSciences Ltd | ₹3,735 cr | - | deleveraging | |
| RPG Life Sciences Ltd | ₹3,689 cr | - | roce compounderearnings quality weaknet cash | |
| SMS Pharmaceuticals Ltd | ₹3,606 cr | - | deleveraging | |
| Aarti Drugs Ltd | ₹3,400 cr | 🔒 unlock to view | latent operating leveragemargin under pressureearnings quality strongdeleveraging | |
| Panacea Biotec Ltd | ₹3,306 cr | - | capex coming onlinenet cashstory tension | |
| Unichem Laboratories Ltd | ₹3,119 cr | - | ||
| Solara Active Pharma Sciences Ltd | ₹2,957 cr | - | deleveragingstory tension | |
| Dishman Carbogen Amcis Ltd | ₹2,893 cr | - | story tension | |
| Morepen Laboratories Ltd | ₹2,734 cr | - | latent operating leverage | |
| Venus Remedies Ltd | ₹2,407 cr | - | earnings quality strongstory tension | |
| Indoco Remedies Ltd | ₹2,284 cr | - | latent operating leveragemargin under pressureearnings quality stronglevering up | |
| Hikal Ltd | ₹2,261 cr | - | latent operating leverageearnings quality strongdeleveragingcapital destroyer | |
| NGL Fine Chem Ltd | ₹1,928 cr | - | capex coming onlinemargin under pressure | |
| Windlas Biotech Ltd | ₹1,752 cr | - | capex coming onlineearnings quality strongnet cash | |
| Hester Biosciences Ltd | ₹1,650 cr | - | earnings quality strongdeleveragingstory tension | |
| Amrutanjan Health Care Ltd | ₹1,616 cr | - | capex coming online | |
| Jagsonpal Pharmaceuticals Ltd | ₹1,422 cr | - | latent operating leverageearnings quality strong | |
| Ind-Swift Laboratories Ltd | ₹1,418 cr | - | margin under pressurenet cash | |
| Syncom Formulations (India) Ltd | ₹1,344 cr | - | net cash | |
| Lincoln Pharmaceuticals Ltd | ₹1,276 cr | - | net cash | |
| Bajaj Healthcare Ltd | ₹1,019 cr | - | earnings quality strongdeleveraging | |
| Wanbury Ltd | ₹964 cr | - | story tension | |
| Themis Medicare Ltd | ₹953 cr | - | margin under pressureearnings quality weakcyclical peak base | |
| Kopran Ltd | ₹884 cr | - | latent operating leveragemargin under pressure | |
| Sigachi Industries Ltd | ₹795 cr | - | latent operating leverage | |
| Kilitch Drugs (India) Ltd | ₹658 cr | - | capex coming onlinestory tension | |
| Zim Laboratories Ltd | ₹611 cr | - | latent operating leveragecapex coming onlineearnings quality strongcapex ahead of revenue | |
| Haleos Labs Ltd | ₹422 cr | - | earnings quality strongdeleveraging | |
| Albert David Ltd | ₹414 cr | - | margin under pressurenet cash | |
| Bafna Pharmaceuticals Ltd | ₹391 cr | - | latent operating leverageearnings quality strong | |
| Valiant Laboratories Ltd | ₹369 cr | - | ||
| Medico Remedies Ltd | ₹351 cr | - | roce compounder | |
| Transchem Ltd | ₹330 cr | - | earnings quality strong | |
| Medicamen Biotech Ltd | ₹313 cr | - | margin under pressure | |
| Lyka Labs Ltd | ₹248 cr | - | earnings quality strongdeleveraging | |
| Nectar Lifescience Ltd | ₹227 cr | - | ||
| Aarey Drugs & Pharmaceuticals Ltd | ₹221 cr | - | earnings quality weak | |
| Brooks Laboratories Ltd | ₹197 cr | - | net cash | |
| Alpa Laboratories Ltd | ₹147 cr | - | latent operating leverageearnings quality weaknet cash | |
| Krebs Biochemicals & Industries Ltd | ₹141 cr | - | latent operating leveragestory tension | |
| Bal Pharma Ltd | ₹138 cr | - | earnings quality stronglevering up | |
| Vineet Laboratories Ltd | ₹65 cr | - | latent operating leveragemargin under pressurelevering up | |
| Biofil Chemicals & Pharmaceuticals Ltd | ₹59 cr | - | ||
| Mangalam Drugs & Organics Ltd | ₹44 cr | - | levering up | |
| Lasa Supergenerics Ltd | ₹36 cr | - | capex coming onlinecapex ahead of revenuecapital destroyer | |
| Ortin Global Ltd | ₹13 cr | - | margin under pressurecapital destroyer |